The prescribing information for Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, per its Drugs@FDA record) says the hydroquinone in the cream may produce exogenous ochronosis, a gradual blue-black darkening of the skin, and that its occurrence should prompt discontinuation of therapy. Reviews, an observational study and an FDA page also describe it. This guide sets out what each source reports and what none of them measures.
How the labels describe it
A prescription hydroquinone USP 4% skin bleaching cream label uses almost the same words in its warnings section. It says hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening of the skin. Its next sentence reads: if this condition occurs, discontinue treatment and consult your physician.
The Tri-Luma label (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) adds that the majority of patients developing this condition are Black, but that it may also occur in Caucasians and Hispanics. That sentence gives no figures.
What the case reviews and an observational study report
A 2022 systematic review selected 56 articles with a total of 126 patients with hydroquinone-associated ochronosis. It reported that ochronosis was most frequently reported with unknown and hydroquinone concentrations greater than 4% (32.5 and 35.7% cases, respectively). Median duration of use was 5 years, with only four cases reported with courses 3 months or shorter and eight cases reported with use 1 year or less. The authors concluded that hydroquinone in concentrations above 4% and in treatment courses longer than 3 months may be associated with new-onset ochronosis.
A 10-year retrospective analysis, an observational study, identified 25 patients with exogenous ochronosis. The average patient used a skin lightening cream for 9.2 years. The condition most commonly arose on the cheeks (68%), forehead (24%), and temples (20%). The abstract does not state which cream or concentration was used.
Both sources describe people who already had ochronosis. Case reports and observational studies cannot show cause and effect, and neither gives a rate among all people who use a hydroquinone product.
What the sources say about cancer
This is a separate question from ochronosis. The Tri-Luma prescribing information (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) states that studies of hydroquinone in animals have demonstrated some evidence of carcinogenicity and that the carcinogenic potential of hydroquinone in humans is unknown.
A 2005 review of hydroquinone as a skin lightener states that there is no report yet demonstrating carcinogenesis resulting from the application of hydroquinone-containing creams. It adds that doctors should be aware of potential health risks which were up until now disregarded.
What the FDA and the leaflet say
The FDA states that it has received reports of serious skin problems from people using skin-lightening products that contain hydroquinone. The problems it names include skin rashes, swelling of the face and discoloration of the skin which may be permanent (a condition called ochronosis). Reports are not a count of how often this happens.
The patient information leaflet for Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) says to stop using the cream and tell a doctor if a blue-black darkening of the skin develops.
What this does not tell you
The sources used here report no trial of hydroquinone 8% or of the four-ingredient blend with tretinoin, niacinamide and vitamin C, so findings at 4% or in other combinations cannot be assumed to apply. The label warnings above belong to Tri-Luma and to a hydroquinone 4% cream label, and they do not describe any other product.
The reviews count reported cases. They do not show how many people used a given strength or duration without developing ochronosis, and the 2022 review lists unknown concentration among the most frequently reported categories. On carcinogenicity, one source calls the human potential unknown and the other says no report yet demonstrates carcinogenesis from hydroquinone-containing creams. Neither gives a measured human figure. A licensed provider decides how any of this applies to a person.